Equities Analysts Offer Predictions for AVDL FY2027 Earnings

Avadel Pharmaceuticals plc (NASDAQ:AVDLFree Report) – HC Wainwright cut their FY2027 earnings per share (EPS) estimates for Avadel Pharmaceuticals in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst O. Livnat now forecasts that the company will post earnings of $1.67 per share for the year, down from their previous estimate of $1.74. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Avadel Pharmaceuticals’ FY2028 earnings at $1.88 EPS.

Other research analysts have also issued research reports about the company. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Avadel Pharmaceuticals in a report on Tuesday. Oppenheimer increased their target price on Avadel Pharmaceuticals from $29.00 to $30.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $24.43.

Get Our Latest Stock Analysis on AVDL

Avadel Pharmaceuticals Price Performance

Shares of AVDL stock traded down $0.30 on Thursday, reaching $11.72. 81,709 shares of the company were exchanged, compared to its average volume of 1,176,766. The company has a 50-day moving average of $13.62 and a 200-day moving average of $15.09. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -15.21 and a beta of 1.47. Avadel Pharmaceuticals has a one year low of $10.39 and a one year high of $19.09.

Avadel Pharmaceuticals (NASDAQ:AVDLGet Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.03. Avadel Pharmaceuticals had a negative net margin of 52.53% and a negative return on equity of 92.12%. The business had revenue of $50.00 million for the quarter, compared to analyst estimates of $48.43 million. During the same period in the prior year, the firm earned ($0.41) earnings per share. Avadel Pharmaceuticals’s revenue was up 624.6% on a year-over-year basis.

Institutional Investors Weigh In On Avadel Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Avadel Pharmaceuticals during the 3rd quarter worth $484,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Avadel Pharmaceuticals during the third quarter worth about $262,000. MetLife Investment Management LLC grew its position in Avadel Pharmaceuticals by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 53,797 shares of the company’s stock worth $706,000 after purchasing an additional 30,313 shares in the last quarter. Townsquare Capital LLC grew its position in Avadel Pharmaceuticals by 18.0% in the 3rd quarter. Townsquare Capital LLC now owns 30,388 shares of the company’s stock worth $399,000 after purchasing an additional 4,629 shares in the last quarter. Finally, FMR LLC bought a new position in shares of Avadel Pharmaceuticals during the 3rd quarter worth approximately $31,000. 69.19% of the stock is owned by hedge funds and other institutional investors.

Avadel Pharmaceuticals Company Profile

(Get Free Report)

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.

Recommended Stories

Earnings History and Estimates for Avadel Pharmaceuticals (NASDAQ:AVDL)

Receive News & Ratings for Avadel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.